Direct-to-Brain attack: new combo targets deadly recurrent tumor
NCT ID NCT06455605
Summary
This early-stage study is testing the safety and effectiveness of a two-part immunotherapy for adults whose aggressive brain cancer (glioblastoma) has returned after initial treatment. After surgery to remove the main tumor, a special combination of two drugs is delivered directly into the remaining tumor area in the brain. Patients then receive follow-up injections of one of the drugs in the neck area for up to a year or longer if they benefit.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA IDH WILDTYPE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University Medical Center
RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.